Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them

Biotechnology

Arrowhead Pharmaceuticals

Jack Shi is the current Vice President of Clinical Pharmacology at [Arrowhead Pharmaceuticals](/org/arrowheadpharma). Prior to this, they served as Executive Director at Ultragenyx Pharmaceutical Inc. from August 2016 to March 2020. Jack has also held the position of Director at [Incyte](/org/incyte) from March 2003 to August 2016, and Sr. Investigator II at [Bristol-Myers Squibb](/org/bristol-myers-squibb) from January 2001 to December 2002. Jack began their career as a Sr. Research Scientist at DuPont Pharmaceuticals in January 1997 and held that position until December 2001.

Jack Shi earned their Doctor of Philosophy (Ph.D.) from [Purdue University](/org/purdue-university) and their B.S. from [Fudan University](/org/fudan-university).

Jack Shi reports to Javier San Martin, CMO. Some of their coworkers include Erik Bush - GVP, Biology, Fred Fleitz - GVP, Chemistry, Manufacturing & Controls, and Peter Carignan - VP, Clinical Operations.

Jack Shi

Dr. San Martin previously served as Senior Vice President and Head of Global Clinical Development at Ultragenyx since 2013, where he led the development of burosumab, a novel drug for the treatment of X-Linked Hypophosphatemia approved across major regions including the United States, the European Union, and Canada. Before his tenure at Ultragenyx, he served as Senior Vice President of Clinic Development at Alder Biopharmaceuticals, where he was responsible for managing the medical, regulatory, and clinical operations group focused on early clinical programs. From 2006 to 2011, Dr. San Martin was a Global Development Leader at [Amgen](/org/amgen), Inc., where he was responsible for two major development programs. He directed the romosozumab clinical program through the end of phase II, and before that, was responsible for the development and approval of denosumab, the largest branded anti-osteoporosis treatment for postmenopausal osteoporosis and the first monoclonal antibody to address a very prevalent disease treated by primary care physicians. Prior to his time at [Amgen](/org/amgen), he spent seven years at Eli Lilly and Company, supporting late stage clinical development as well as medical affairs activities, including the successful launch of Evista and Forteo. He received his medical degree from the University of Buenos Aires Medical School and completed his residence in internal medicine at CEMIC University Hospital in Buenos Aires, Argentina, serving as Chief Resident, and, thereafter, as Attending Physician responsible for the internal medicine ward.

Javier San Martin

Ken Myszkowski is the CFO at [Arrowhead Pharmaceuticals](/org/arrowheadpharma). Ken has previously served as corporate controller at [Broadwind Energy](/org/broadwind-energy) and as director of finance and controller at NanoInk, Inc. and Delphion, Inc. Ken has also worked as a senior analyst at FMC Corporation and as a controller at Primary Energy Recycling Corp / Epcor USA. Ken Myszkowski began their career as an auditor at Arthur Andersen & Co. in 1988 and has also held positions as manager of internal audit and investor relations at Premark International.

Ken Myszkowski has an MBA in Finance from The University of Chicago Booth School of Business and a BA in Accounting from University of Illinois Urbana-Champaign. Ken also has certification from American Institute of Certified Public Accountants in CPA.

Some of their coworkers include Randy Steiner - VP, Regulatory Affairs, Dave Bormett - VP, Quality Assurance, and Jane Davidson - VP, Human Resources. Their manager is Christopher Anzalone, President & CEO. Some direct reports include Vincent Anzalone - VP & Head of Investor Relations, Matt Pulisic - VP of Finance.

Ken Myszkowski

Robert Teigen is the Vice President of Intellectual Property and Associate General Counsel at [Arrowhead Pharmaceuticals](/org/arrowheadpharma). Robert has also been a partner at RAKOCZY MOLINO MAZZOCHI SIWIK LLP, where they worked for eight years before their current position.

Mr. Teigen is registered to practice before the United States Patent and Trademark Office and holds a degree in Biochemistry. Their experience with litigation surrounds the patent infringement and invalidity under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act. Robert is also experienced in regulatory counseling and litigation under the Administrative Procedure Act. In addition, they have filed citizen petitions, related comments, and other administrative submissions with the U.S. Food and Drug Administration.

Robert Teigen has a Juris Doctor from DePaul University College of Law and a B.A. in Biochemistry from Saint John's University. Robert also attended Totino-Grace High School.

Their manager is Patrick C. O’Brien, COO & General Counsel.

Robert Teigen

Fred Fleitz is the GVP of Chemistry, Manufacturing, & Controls at [Arrowhead Pharmaceuticals](/org/arrowheadpharma). Fred has over 10 years of experience in the pharmaceutical industry, with a focus on process R&D. 

Fleitz started their career at Cambridge Major Laboratories, Inc. in September 2010 as a Senior Manager of Process R&D. In this role, they were responsible for optimizing synthetic routes to target compounds, establishing key reaction parameters and stability/hold points, identifying and minimizing impurity formation, and ensuring suitability of processes for scale up to fixed equipment. Fred also managed a group of two PhDs and their associates in support of client developmental programs. In 2012, Fleitz became the primary reviewer of all Request for Quotations, and in 2013 they became the liaison to the Scientific Advisory Board. Fred left Cambridge Major Laboratories in June 2014 to join [Arrowhead Pharmaceuticals](/org/arrowheadpharma). 

At [Arrowhead Pharmaceuticals](/org/arrowheadpharma), Fleitz is responsible for chemistry, manufacturing, and controls. Fred has overseen the successful launch of several products and is an expert in Design of Experiments (DOE) and statistical analysis. Under their leadership, [Arrowhead](/org/arrowhead-promotion-fulfillment-company-inc) has become a leading player in the pharmaceutical industry.

Fred Fleitz earned their Ph. D. in organic chemistry from [Stanford University](/org/stanford). Fred also holds a Bachelor of Science (B.S.) in chemistry from [Miami University](/org/miami-university).

They are on a team with Peter Carignan - VP, Clinical Operations, Erik Bush - GVP, Biology, and Christine Esau - VP, Biology. Fred Fleitz reports to Javier San Martin, CMO.

Fred Fleitz

Dr. Christopher Anzalone has been President, Chief Executive Officer and Director of the Company since December 1, 2007. In 2005, Dr. Anzalone formed and served as CEO of the Benet Group LLC, a private equity firm focused on creating and building new nano-biotechnology companies from university-generated science. Prior to his tenure at the Benet Group, he was a partner at the Washington, DC-based private equity firm Galway Partners, LLC, where he was responsible for sourcing, structuring, and building new business ventures. Prior to Galway, Dr. Anzalone was an NIH-supported post doctoral fellow in Reproductive Endocrinology at the [Smithsonian Institution](/org/smithsonian-institution)’s Conservation and Research Center. Dr. Anzalone holds a Ph.D. in Biology from UCLA and a B.A. in Government from [Lawrence University](/org/lawrence-university).

Christopher Anzalone

Will Waddill began his career 30 years ago in commercial banking and public accounting and has been in the biotechnology industry for over 25 years. Currently he sits on the boards of Protagonist Therapeutics and Arrowhead Pharmaceuticals. Most recently he was Senior Vice President, CFO of Calithera Bioscience where he completed over $106 million in equity financing including the company’s $80 million IPO in October 2014. Prior to Calithera, Mr. Waddill was Senior Vice President, CFO, at OncoMed Pharmaceuticals from 2007 to 2014, where he was responsible for all corporate financial matters, most notably their $94 million Initial Public Offering in 2013, private equity financings of $126 million, and three collaborations valued at $6.1 billion. Prior to OncoMed, Will was Senior Vice President, CFO, at Ilypsa, where he was the finance lead for the companies $420 million acquisition by Amgen. Before joining Ilypsa, he was the founder and principal at Square One Finance, a life science consulting business managing the finances of 33 start-up biotechnology companies including eight that became public and six that have been acquired. In addition to being on the boards of Protagonist and Arrowhead, Will is an emeritus board member of the Association of Bioscience Financial Officers (ABFO), where he was Chairman in 2016 as well as co-chair of the ABFO 2014 National Conference. Formerly he served as Chairman of the Biotechnology Industry Organization (BIO) BIO Business Solutions Advisory Board as well as the Finance and Tax Committee. Will has testified in Washington D.C. on behalf of the biotech industry in front of the Senate Finance Committee and Congressional Capital Markets Subcommittee. He received a BS in accounting from the University of Illinois, Chicago, and certification as a public accountant (inactive) after working at PriceWaterhouseCoopers and Deloitte in Boston.

William Waddill

Dr. Michael S. Perry joined Arrowhead’s Board of Directors in December 2011. Dr. Perry is currently the Chief Executive Officer of Avita Medical (ASX: AVH and OTCQX: AVMXY). From 2014 until June 2017, Dr. Perry served as Chief Scientific Officer of Novartis’ Cell and Gene Therapy Unit and from 2012 until 2014 he served as Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp, a US affiliate of Switzerland-based Novartis AG.  Prior to his appointment at Novartis, Dr. Perry was a Venture Partner with Bay City Capital LLP from 2005 until November 2012 and President and Chief Medical Officer of Poniard Pharmaceuticals from 2010 to November 2012. He also currently serves as a member of the board of directors of AmpliPhi Biosciences Corporation and Avita Medical. He was Chief Development Officer at VIA Pharmaceuticals, Inc., a publicly held drug development company, from April 2005 until May 2009. Prior thereto, he served as Chairman and Chief Executive Officer of Extropy Pharmaceuticals, Inc., a privately held pediatric specialty pharmaceutical company, from June 2003 to April 2005. From 2002 to 2003, Dr. Perry served as President and Chief Executive Officer of Pharsight Corporation, a publicly held software and consulting services firm. From 2000 to 2002, Dr. Perry served as Global Head of Research and Development for Baxter BioScience. From 1997 to 2000, Dr. Perry was President and Chief Executive Officer of both SyStemix Inc. and Genetic Therapy Inc., two wholly owned subsidiaries of Novartis Corp. and from 1994 to 1997, he was Vice President of Regulatory Affairs for Novartis Pharma (previously Sandoz Pharmaceuticals). Prior to 1994, Dr. Perry held various management positions with Syntex Corporation, Schering-Plough Corporation and BioResearch Laboratories, Inc. Dr. Perry holds a Doctor of Veterinary Medicine, a Ph.D. in Biomedical Pharmacology and a B.Sc. in Physics from the University of Guelph, Ontario, Canada. He is a graduate of the International Management Program at Harvard Business School. We believe Dr. Perry’s qualifications to serve on the board include his medical expertise and his extensive experience in preclinical and clinical drug development, including executive level leadership roles in several publicly held biotech companies.

Michael Perry

Dr. Mauro Ferrari was appointed to the Arrowhead Board of Directors in 2010. Dr. Ferrari currently serves as Professor of Pharmaceutics at the University of Washington in Seattle, WA and CEO of DXT Pharmaceutics in Menlo Park, CA.

In the decade 2010-2019, he was President and CEO of The Houston Methodist Hospital Research Institute (TMHRI), where he also served as Executive Vice President of Houston Methodist Hospital, and Senior Associate Dean of Weill Cornell Medical College in New York. He also served as President of the European Research Council. Dr. Ferrari is an internationally recognized expert in nanomedicine and biomedical nanotechnology. Prior to assuming leadership of TMHRI, Dr. Ferrari was Professor and Chairman of The Department of NanoMedicine and Biomedical Engineering at The University of Texas Health Science Center at Houston, Professor of Experimental Therapeutics at the MD Anderson Cancer Center, Adjunct Professor of Bioengineering at Rice University, and Adjunct Professor of Biomedical Engineering at the University of Texas in Austin. His previous academic appointments include tenured professorships at his graduate Alma Mater UC Berkeley, and The Ohio State University.

From 2003 to 2005, Dr. Ferrari served as Special Expert on Nanotechnology and Eminent Scholar at The National Cancer Institute, where he led in the development of NCI’s program in Nanotechnology, which remains the largest program in NanoMedicine in the world. Dr. Ferrari has been serving as the Editor-in-Chief for “Biomedical Microdevices: BioMEMS and Biomedical Nanotechnology” since 1997. We believe Dr. Ferrari’s qualifications to serve on the Board include his extensive training and experience in the fields of nanotechnology, biotechnology and biomedical applications. Dr. Ferrari has significant technical training in mathematics, engineering, medicine, and business, about 500 published articles, over 50 issued patents, and is the recipient of most prestigious academic awards in nanomedicine, the pharmaceutical sciences, and drug delivery technology. Additionally, Dr. Ferrari has extensive experience in developmental stage organizations having founded several startup companies.

Mauro Ferrari

Doug is Managing Partner at Health2047 Capital Partners LLC 2018-present. He served as Health2047 lnc.’s Chief Executive from its founding in 2015 until 2018. Doug has spent more than two decades in venture capital as an Investment Partner and General Partner at life sciences investor Bay City Capital LLC participating in five sequential life sciences general funds and two sector-specific funds; he was associated with the partnership from 1999-2015. Doug is a physician and medical scientist. Beginning in 1983 he has been a global corporate and operating executive at Lilly, Monsanto, Schering Plough and Mallinckrodt and a serial entrepreneur. In addition to a number of private companies, he led three public biopharmaceutical companies as CEO.

Doug has served on more than 20 public and private boards. He is currently a Director at Health2047 Inc, Board Chair at Arrowhead Pharmaceuticals (NASDAQ:ARWR), Managing Partner at GS Partners LLC, and serves on the board at First Mile Care Inc, BrYet Health Ltd, Visirna Therapeutics, and Vivaldi Biosciences Inc. He serves in advisory roles on the University of Chicago Pritzker School of Medicine, and Biological Sciences Division Council (former Chair), Johns Hopkins Bloomberg School of Public Health, Health Advisory Board.

Doug received MD and PhD degrees from the University of Chicago, an MBA from the Wharton School at the University of Pennsylvania and was a Clinical and Research Fellow in internal medicine ancf infectious diseases at Massachusetts General Hospital and Harvard Medical School.

Douglas Given

Peter Carignan

Tracie Oliver, Chief Commercial Officer, joined Arrowhead in June 2022.  Ms. Oliver has over 30 years of global experience in the biopharmaceutical industry leading both R&D and Commercial organizations. Prior to joining Arrowhead, she had her own consulting practice focused on development of commercial and development strategy for small biotech companies.  She joined Shire Pharmaceuticals in 2016 through the acquisition of Baxalta and was Global Head of New Product Planning and Device Strategy.  Prior to that she held several commercial roles at Baxter and Baxalta including establishing a new oncology franchise and leading the North America Immunology Business Unit and Autoimmune Franchise.  Ms. Oliver began her career in the biopharmaceutical industry with Johnson & Johnson and served as head of Ortho Biotech Nephrology Business Unit in Canada, Ortho McNeil Neurologics, and McNeil Pediatrics in the USA and led an internal venture developing an allogeneic cell therapy for acute ischemic stroke. She received her BSc and MSc from Queen’s University in Kingston, Ontario and her MBA from the Shulich School of Business, York University, Toronto.

Tracie Oliver

Victoria Vakiener currently serves on the board of directors of Chimerix, a clinical-stage biopharmaceutical company. From November 2018 through September 2021, she served as Chief Commercial Officer of Epizyme, Inc. where she built the commercial organization and launched TAZVERIK for two indications within six months.  Prior to joining Epizyme, Ms. Vakiener was an executive at Johnson & Johnson for more than twenty years where she held positions of leadership with increasing responsibility across the company’s pharmaceutical and diagnostics businesses. Ms. Vakiener began her pharmaceutical career at Schering-Plough, where she spent nine years in both scientific and commercial roles.  Ms. Vakiener received a B.S. in Biochemistry from Albright College.

Victoria Vakiener

Leslie Lemke-Boutcher

Matt Pulisic

Patrick C. O’Brien, General Counsel, joined the Company in December 2014. Mr. O’Brien has practiced in the healthcare legal field for over 20 years. Before joining the Company, from 2012 to 2014, Mr. O’Brien was with Shire, where he was Group Vice President, Law. Immediately prior to working with Shire he was a partner with the international law firm of Holland & Knight LLP in its Washington, DC office. In 2010, Mr. O’Brien co-founded the law firm O’Brien Gould PLLC which joined Holland & Knight in 2011. From 2009 – 2010, Mr. O’Brien was a partner in Burke O’Neil LLC. From 2001 – 2009 Mr. O’Brien served in several legal roles with Johnson & Johnson, including serving as Vice President of Law for J&J’s Centocor Ortho-Biotech unit. Mr. O’Brien previously served as Regulatory Counsel with the United States Food & Drug Administration. Mr. O’Brien was awarded a BS in Pharmacy and a PharmD from the University of Arizona before completing a residency in Clinical Pharmacy with the University of Illinois at Chicago Hospital. He was also awarded his JD from the University of Arizona.

Patrick C. O’Brien

Christine Esau

Erik Bush

Tao Pei

Zhi-Ming Ding

James Hamilton

Vincent Anzalone

Oye Olukotun is a [Mayo Clinic](/org/mayo-clinic) trained Cardiologist who currently serves as the Chief Executive Officer of CR Strategies, LLC. He served as the CEO of Epigen Pharmaceuticals, Inc. from 2014 to 2017, and Vice Chairman of CardioVax, Inc., from 2012 to 2016. He spent the first 20 years of his career in roles of increasing responsibility in clinical development, including multiple product approvals, at [Pfizer](/org/pfizer), [Bristol-Myers Squibb](/org/bristol-myers-squibb), and [Mallinckrodt](/org/mallinckrodt). He has over 35 years of experience in the pharmaceutical industry and has been instrumental in the approval and success of numerous cardiology and metabolic medicines, including the first daily beta blocker and the first approved ACE inhibitor, among others. Dr. Olukotun currently serves on the board of directors for Tonix Pharmaceuticals Holding Corp. Dr. Olukotun received his Medical Doctor degree from the Albert Einstein College of Medicine in New York, and a Masters in Public Health from [Harvard University](/org/harvard) School of Public Health.



Oye Olukotun

Dave Bormett

Marianne De Backer is currently Executive Vice President, Head of Global Business Development & Licensing, and a member of the Executive Committee of the Pharmaceuticals Division of [Bayer](/org/bayer) AG. Before joining [Bayer](/org/bayer), Dr. De Backer held a series of positions in the [Johnson & Johnson](/org/johnson-johnson) family of companies. She started as a scientist and scientific group leader during which time her work resulted in multiple patents. She progressed through commercial positions internationally including leading a sales and marketing business unit responsible for several product lines, culminating as Vice President, M&A Operations, Divestitures, and Janssen Business Development. During her tenure with [Johnson & Johnson](/org/johnson-johnson), Dr. De Backer had direct accountability for over 200 strategic alliances. Dr. De Backer received a MSc in Molecular Biology from the University of Brussels, Belgium, a Masters in Engineering and Biochemistry and a Ph.D. in Biotechnology from the University of Ghent, Belgium, and an MBA from Rotterdam School of Management, Erasmus University, The Netherlands.

Marianne De Backer

Randy Steiner

Thomas Schluep is the current VP of Program Management at [Arrowhead Pharmaceuticals](/org/arrowheadpharma). Thomas has over 15 years of experience in the field of pharmaceuticals, with a focus on drug delivery and development. 

Thomas started their career at Insert Therapeutics, where they were responsible for the planning, management, and oversight of the company's drug discovery and development programs. During their time there, they successfully brought IT-101, the company's lead anticancer compound, from bench to clinic in less than 2 years.

In 2008, they left Insert Therapeutics to join Calando Pharmaceuticals as their CSO. At Calando, they oversaw the company's research and development activities, including their clinical siRNA candidate (CALAA-01), which was the first targeted and fully formulated siRNA therapeutic to enter the clinic. In June 2009, they helped negotiate a deal that saw Calando's IT-101 and Cyclosert drug delivery platform being out-licensed for > $35 million.

Thomas joined [Arrowhead Pharmaceuticals](/org/arrowheadpharma) in July 2009 and has since been overseeing the company's program management activities. Under their leadership, [Arrowhead](/org/arrowhead-promotion-fulfillment-company-inc) has continued to grow and develop new therapeutics that are making a difference in the lives of patients around the world.

Thomas Schluep received a Sc.D. in Process Engineering from [ETH Zürich](/org/eth-zurich) and a Diploma in Biotechnology from [ETH Zürich](/org/eth-zurich).

They are on a team with Randy Steiner - VP, Regulatory Affairs, Tracie Oliver - Chief Commercial Officer, and Jane Davidson - VP, Human Resources. Their manager is Christopher Anzalone, President & CEO.

Arrowhead Pharmaceuticals

Org chart

Teams

Leadership Team

Board of Directors

CEO and Executive Team

Discover similar companies